Science Star over Asia 英文参考文献.docVIP

Open access, freely available online Essay Science Star over Asia Chris Y. H.Tan R ecent news of human embryonic stem cell (hESC) research in Seoul has made headlines around the world. In 2004, Korea took the world by surprise when W. S. Hwang and his team outsourcing to discover new medicine. Amazingly, for a latecomer to modern drug development, there are now 140 drugs in China’s pipeline alone, 60 (10% of the world’s total) of which are biologically derived agents, including antibodies and vaccines. And in the near future, it is likely that numerous clinical trials will be performed in Asia applied the TCM principle of using one poison to counter another—they have used sublethal doses of tetrodotoxins for the treatment of pain associated with heroin withdrawal [5] and for the management of pain in patients with cancer [6]. published the isolation of hESCs from a cloned blastocyst [1]. One year later, the same Korean team published the establishment of 11 hESC lines, made from transplanting the nucleus of patients’ skin cells into donated human oocytes [2]. But few in the Western science community are aware that hESC research has its root in Asia. Ariff Bongso and his associates at Singapore’s National University Hospital in 1994 were the ?rst to derive hESCs from a ?ve-day-old discarded human embryo and discover that these cells were pluripotent and, henceforth, had therapeutic potentials as cell transplants [3]. Eight years later, they were able to substitute the use of mouse feeder layer cells with human cell feeders and human serum to grow hESCs, reducing the risk of introducing mouse and bovine pathogens [4] when hESCs are transplanted into patients. The stem cell success in Korea comes out of a history in and growing investment in Asia–Paci?c science that the West is slowly appreciating. It also comes at a time when independent events in the United States are having an impact on clinical research and health care. The ongoing debate of the Right to Life